Elaina P Weldon

Plain English
A gene-edited pig kidney was transplanted into a brain-dead human and kept functioning for a planned 61-day study using only standard approved anti-rejection drugs. The kidney maintained stable electrolyte balance and eliminated the need for dialysis, but antibody-mediated rejection emerged on day 33 and was reversed with plasma exchange and complement inhibition. The study shows a minimally modified pig kidney can sustain human-equivalent kidney function and identifies pre-existing immune cells reactive to pig tissue as a key obstacle to long-term success.

Plain English
This study looked at the long-term results of using a drug called imlifidase to help people with kidney transplants when their body was likely to reject the new kidney due to pre-existing antibodies. After five years, most participants were doing well: 7 out of 8 were alive, and although a few experienced issues related to their antibodies early on, these were effectively managed. This matters because it shows that using imlifidase allows for successful kidney transplants in difficult cases, and even though some antibodies returned, they were weaker and didn't cause significant problems in the long term.

Plain English
This pilot study tested whether a 14-day course of the hepatitis C drug combination glecaprevir/pibrentasvir, started just before transplant, could safely prevent or clear hepatitis C transmitted from infected donor kidneys. All 20 recipients achieved a sustained virus-free response with no relapses at one year, and 35% never developed detectable virus at all. The results support using a two-week prophylactic course as a safe and effective strategy that expands the pool of usable donor kidneys.

Plain English
Researchers transplanted a pig kidney-thymus combination into a deceased human and tracked the immune response over 61 days. T cells from the recipient infiltrated the organ and specific clones expanded in blood, tissue, and lymph nodes around rejection events. This reveals that T cell-driven rejection of pig organs in humans closely mirrors what happens with human-to-human transplants, informing how future immunosuppression strategies must be designed.

Plain English
This study looked at transplanting genetically modified pig hearts into two recently deceased human patients to see how well they would function. Both pig hearts worked well right after the transplant, but one heart eventually had problems due to being too large for the recipient. Importantly, there were no signs that the human bodies rejected the hearts or that any diseases were passed from pigs to humans, which is a significant step forward in addressing the shortage of human organs for transplant.

Plain English
This study looked at the risks of family caregivers getting hepatitis C from patients who received organs from hepatitis C-infected donors. Out of 182 patients who received these organs, three caregivers reported accidental needle stick injuries, which is about 1.64% of the cases. Thankfully, none of the caregivers ended up contracting the virus, but the researchers emphasized the need for clear communication about these risks to families and better protocols for monitoring and treatment if exposure does happen.

Plain English
This study examined whether giving a medication called verapamil during kidney transplants from donors who had died from cardiac arrest could improve kidney function after surgery. The researchers looked at 186 kidney transplant patients—93 who received verapamil and 93 who did not—and found no significant difference in the rate of kidney issues after the transplant; both groups experienced similar rates of delayed graft function (DGF). The study highlights that cold ischemia time, the period the kidney spent outside the body before transplantation, was the only factor linked to DGF, emphasizing the need to minimize this time for better outcomes.

Plain English
This randomized controlled trial tested whether clazakizumab, a drug that blocks the inflammatory signal interleukin-6, could help hospitalized COVID-19 patients with dangerous levels of inflammation. Patients receiving the drug had nearly four times better odds of surviving 28 days without a ventilator and were significantly less likely to need ICU admission or mechanical ventilation. Clazakizumab substantially improved survival and clinical outcomes, supporting its use for severe COVID-19 with hyperinflammation.

Plain English
This study looked at two different ways to treat hepatitis C infections in patients who received organs from donors with the virus. They found that patients who received financial help to start treatment right away began their therapy much sooner (about 4 days compared to 10 days) and had shorter periods of the virus in their systems (16 days instead of 36 days). While providing this financial support increased costs for the hospital (around $9,173 per patient with support versus $168 without), treating patients sooner is better for their health and should lead to changes in how insurance processes work for these cases.

Plain English
Researchers studied a new drug called IdeS, which helps patients with specific antibodies that would normally prevent them from receiving a kidney transplant. In a trial with 7 highly sensitized patients, IdeS successfully cleared these harmful antibodies before their transplants, allowing all the patients to receive kidneys from their donors, even those who had previously been ruled out due to positive crossmatches. This treatment is important because it offers new hope for patients who have been difficult to match for transplants, improving their chances of receiving lifesaving organ transplants.